204 related articles for article (PubMed ID: 22374758)
1. CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs.
Kim SP; Woolcott OO; Hsu IR; Stefanoski D; Harrison LN; Zheng D; Lottati M; Kolka C; Catalano KJ; Chiu JD; Kabir M; Ionut V; Bergman RN; Richey JM
Am J Physiol Endocrinol Metab; 2012 May; 302(10):E1261-8. PubMed ID: 22374758
[TBL] [Abstract][Full Text] [Related]
2. CB1R antagonist increases hepatic insulin clearance in fat-fed dogs likely via upregulation of liver adiponectin receptors.
Kabir M; Iyer MS; Richey JM; Woolcott OO; Asare Bediako I; Wu Q; Kim SP; Stefanovski D; Kolka CM; Hsu IR; Catalano KJ; Chiu JD; Ionut V; Bergman RN
Am J Physiol Endocrinol Metab; 2015 Oct; 309(8):E747-58. PubMed ID: 26306598
[TBL] [Abstract][Full Text] [Related]
3. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
Tam J; Godlewski G; Earley BJ; Zhou L; Jourdan T; Szanda G; Cinar R; Kunos G
Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E457-68. PubMed ID: 24381003
[TBL] [Abstract][Full Text] [Related]
4. Does rimonabant independently affect free fatty acid and glucose metabolism?
Triay J; Mundi M; Klein S; Toledo FG; Smith SR; Abu-Lebdeh H; Jensen M
J Clin Endocrinol Metab; 2012 Mar; 97(3):819-27. PubMed ID: 22170727
[TBL] [Abstract][Full Text] [Related]
5. Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs.
Richey JM; Woolcott OO; Stefanovski D; Harrison LN; Zheng D; Lottati M; Hsu IR; Kim SP; Kabir M; Catalano KJ; Chiu JD; Ionut V; Kolka C; Mooradian V; Bergman RN
Am J Physiol Endocrinol Metab; 2009 Jun; 296(6):E1311-8. PubMed ID: 19366874
[TBL] [Abstract][Full Text] [Related]
6. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice.
Jourdan T; Djaouti L; Demizieux L; Gresti J; Vergès B; Degrace P
Diabetes; 2010 Apr; 59(4):926-34. PubMed ID: 20110567
[TBL] [Abstract][Full Text] [Related]
7. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog.
Kim SP; Ellmerer M; Van Citters GW; Bergman RN
Diabetes; 2003 Oct; 52(10):2453-60. PubMed ID: 14514627
[TBL] [Abstract][Full Text] [Related]
8. Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice.
Migrenne S; Lacombe A; Lefèvre AL; Pruniaux MP; Guillot E; Galzin AM; Magnan C
Am J Physiol Regul Integr Comp Physiol; 2009 Apr; 296(4):R929-35. PubMed ID: 19211723
[TBL] [Abstract][Full Text] [Related]
9. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.
Wang Q; Perrard XD; Perrard JL; Mansoori A; Smith CW; Ballantyne CM; Wu H
Obesity (Silver Spring); 2011 Mar; 19(3):505-13. PubMed ID: 20885384
[TBL] [Abstract][Full Text] [Related]
10. Large size cells in the visceral adipose depot predict insulin resistance in the canine model.
Kabir M; Stefanovski D; Hsu IR; Iyer M; Woolcott OO; Zheng D; Catalano KJ; Chiu JD; Kim SP; Harrison LN; Ionut V; Lottati M; Bergman RN; Richey JM
Obesity (Silver Spring); 2011 Nov; 19(11):2121-9. PubMed ID: 21836643
[TBL] [Abstract][Full Text] [Related]
11. Selective cannabinoid-1 receptor blockade benefits fatty acid and triglyceride metabolism significantly in weight-stable nonhuman primates.
Vaidyanathan V; Bastarrachea RA; Higgins PB; Voruganti VS; Kamath S; DiPatrizio NV; Piomelli D; Comuzzie AG; Parks EJ
Am J Physiol Endocrinol Metab; 2012 Sep; 303(5):E624-34. PubMed ID: 22761159
[TBL] [Abstract][Full Text] [Related]
12. Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet.
Flamment M; Gueguen N; Wetterwald C; Simard G; Malthièry Y; Ducluzeau PH
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1162-70. PubMed ID: 19724020
[TBL] [Abstract][Full Text] [Related]
13. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.
Cota D; Sandoval DA; Olivieri M; Prodi E; D'Alessio DA; Woods SC; Seeley RJ; Obici S
Obesity (Silver Spring); 2009 Aug; 17(8):1641-5. PubMed ID: 19325539
[TBL] [Abstract][Full Text] [Related]
14. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity.
Ravinet Trillou C; Delgorge C; Menet C; Arnone M; Soubrié P
Int J Obes Relat Metab Disord; 2004 Apr; 28(4):640-8. PubMed ID: 14770190
[TBL] [Abstract][Full Text] [Related]
15. The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction.
Lim SY; Davidson SM; Yellon DM; Smith CC
Basic Res Cardiol; 2009 Nov; 104(6):781-92. PubMed ID: 19462153
[TBL] [Abstract][Full Text] [Related]
16. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG
Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481
[TBL] [Abstract][Full Text] [Related]
17. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.
Nogueiras R; Veyrat-Durebex C; Suchanek PM; Klein M; Tschöp J; Caldwell C; Woods SC; Wittmann G; Watanabe M; Liposits Z; Fekete C; Reizes O; Rohner-Jeanrenaud F; Tschöp MH
Diabetes; 2008 Nov; 57(11):2977-91. PubMed ID: 18716045
[TBL] [Abstract][Full Text] [Related]
18. Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade.
Crespillo A; Suárez J; Bermúdez-Silva FJ; Rivera P; Vida M; Alonso M; Palomino A; Lucena MA; Serrano A; Pérez-Martín M; Macias M; Fernández-Llébrez P; Rodríguez de Fonseca F
Biochem J; 2011 Jan; 433(1):175-85. PubMed ID: 20955176
[TBL] [Abstract][Full Text] [Related]
19. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
Després JP; Ross R; Boka G; Alméras N; Lemieux I;
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
[TBL] [Abstract][Full Text] [Related]
20. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.
Merroun I; Sánchez-González C; Martínez R; López-Chaves C; Porres JM; Aranda P; Llopis J; Galisteo M; Zarzuelo A; Errami M; López-Jurado M
Metabolism; 2013 Nov; 62(11):1641-50. PubMed ID: 23932644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
